BioMAS
 

Targeting Integrins with safe small
Tellurium molecules

BioMAS Ltd. is a clinical stage company, the only known company worldwide to focus on the invention, development and commercialization of tellurium based compounds. The Company’s lead molecules AS101 and SAS, are small tellurium based compounds developed for the treatment of various conditions.
The molecules developed by BioMAS have Integrin inhibitory properties based on their interaction with specific thiols. Integrins are emerging therapeutic targets in many human pathologies... More...


Pipeline

AS101

  Preclinical Phase I Phase II Out-Licensed  
  B  
Human Papilloma
Virus Warts (HPV)
   
Myelosuppression /
Malignancies
   
Age Related Macular
Degeneration (AMD)
   

SAS

   

BioMAS Ltd.

The Hebrew University of Jerusalem | Edmond J. Safra Campus, Givat Ram | High-Tech Village, POB 39106, Jerusalem | Israel 91390
 Tel: +972-72-2204000, Fax: +972-72-2204008, E-mail: info@biomas-pharma.com